MARKET RADAR
SENSEX     NIFTY      Refresh
Moneycontrol.com India | Accounting Policy > Pharmaceuticals > Accounting Policy followed by Vivo Biotech - BSE: 511509, NSE: N.A
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > ACCOUNTING POLICY - Vivo Biotech
Vivo Biotech
BSE: 511509|ISIN: INE380K01017|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
25, :
13.05
0
VOLUME 0
Vivo Biotech is not listed on NSE
« Mar 11
Accounting Policy Year : Mar '12
General:
 
 (I) These accounts are prepared on the historical cost basis and on the
 accounting principles of a going concern.
 
 (ii) Accounting policies not specifically referred to otherwise are
 consistent and in consonance with generally accepted accounting
 principles.
 
 Revenue Recognition:
 
 (I) The Company follows the mercantile system of Accounting and
 recognizes income and expenditure on accrual basis.
 
 (ii) Revenue is not recognized on the grounds of prudence, until
 realized in respect of liquidated damages, delayed payments as recovery
 of the amounts are not certain.
 
 Fixed Assets:
 
 (a) Fixed assets are stated at cost less accumulated depreciation. Cost
 of acquisition of fixed assets is inclusive of freight, duties, taxes
 and incidental expenses thereto.
 
 (b) Capital Expenditure with respect to Research and Development
 Activities is capitalized from the date of completion and ready for
 use.
 
 Depreciation and Amortization:
 
 (i) Depreciation is provided on straight line method on pro-rata basis
 and at the rates and manner specified in the Schedule XIV of the
 Companies Act, 1956.
 
 (ii) Preliminary Expenses are amortized over the period of 10 years.
 
 iii) Depreciation on Technical Know how not created because revenues
 relating to the same not generated during the financial year.
 
 Research and Development Expenses:
 
 Costs related to internal research and development programs are
 expensed as incurred.
 
 Borrowing Costs:
 
 Borrowing costs attributable to the acquisition or construction of
 qualifying assets are capitalized as part of the cost of such assets. A
 qualifying asset is one that necessarily takes substantial period of
 time to get ready for intended use. All other borrowing costs are
 charged to revenue.
 
 Inventories:
 
 Inventories are valued at cost or market price which ever is lower.
 
 Impairment:
 
 At each balance sheet date, the Company reviews the carrying amounts of
 its fixed assets to determine whether there is any indication that
 those assets suffered an impairment loss. If any such indication
 exists, the recoverable amount of the asset is estimated in order to
 determine the extent of impairment loss. Recoverable amount is the
 higher of an asset''s net selling price and value in use. In assessing
 value in use, the estimated future cash flows expected from the
 continuing use of the asset and from its disposal are discounted to
 their present value using a pre-discount rate that reflects the current
 market assessments of time value of money and the risks specific to the
 asset.
 
 Reversal of impairment loss is recognized immediately as income in the
 Profit and Loss account.
 
 Gratuity:
 
 The Company has made provision for the gratuity to its employees as per
 the provisions of the Payment of Gratuity Act, 1972
Source : Dion Global Solutions Limited
Quick Links for vivobiotech
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.